Abbott’s New Coronary Imaging Software Powered by Artificial Intelligence Launched in India

  • Ultreon™ 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography (OCT) with the power of automation using Artificial Intelligence (AI)
  • Streamlined and intuitive, Ultreon™ 1.0 Software provides step by step guidance to physicians, enhances ease of use and gives better insights to optimize patient outcomes

MUMBAI, India, 16 October 2023 — Abbott today announced that it has launched its new vascular imaging platform powered by Ultreon 1.0 Software in India. This first-of-its-kind intra-vascular imaging software combines optical coherence tomography (OCT) with the power of artificial intelligence (AI) providing physicians a comprehensive view of blood flow and blockages within coronary arteries. The innovative imaging software can automatically differentiate between a calcified and non-calcified blockage, detect the severity of calcium-based blockages and measure vessel diameter. In addition, it helps physicians guide precise stent deployment, ensure optimal stent expansion and apposition with instantaneous display of results to enhance precision during coronary stenting procedures.

Unlike traditional imaging methods such as conventional angiography, Abbott’s OCT technology uses near-infrared light to provide high-definition, precise imaging from within a blood vessel, allowing physicians to capture information from even the most complex patient anatomy. The software enables a streamlined workflow that facilitates accurate and faster decision-making, reduces ambiguities to focus on what's most important: caring for the patient and improving their quality of life.

With the launch of Ultreon 1.0 Software, Abbott is further leveraging OCT technology to help physicians make better treatment decisions for their patients. Recent data show that physicians altered their treatment strategy in 88% of coronary artery blockages based on new information provided by OCT when used with MLD MAX, a new workflow that helps guide stenting decisions and provide physicians with treatment strategies to optimize stent placement.[i]

"Ultreon’s customizable user interface and AI detection will make decision-making faster and reduce procedural variability," said Dr. Ajith Pillai from Kauvery Hospital, Chennai, "The automatic display of details with Ultreon reduces uncertainty during the preparation for stent placement, provides real-time, high-resolution imaging and allows for increased accuracy to deliver better care to patients."

Technology continues to be a vital part of improving patient care with cardiovascular disease. In market research commissioned by Abbott titled Beyond Intervention in August 2020, physicians and administrators identified technology as a critical component to improving patient outcomes across the healthcare continuum. According to the research, 83.2% of physicians agreed that advances in diagnostic and treatment technologies, such as OCT, have translated to tangible improvements in patient care.[i] Ultreon Software is an example of technology designed to augment physician decision-making, particularly when combined with established tools providing comprehensive physiological assessment of coronary blood flow and severity of blockages. With the rising burden of cardiovascular diseases in India, it is our constant effort to bring newer technologies into the country, offering physicians the tools needed to provide the highest level of care and best possible outcomes for patients. 

"Increased adoption of OCT imaging, when combined with advanced technology like AI, allows cardiologists to have a more precise and measurable way of supporting patients undergoing coronary stent procedures," said Tushar Sharma, General Manager for Abbott’s vascular business in India and South Asia. "Ultreon 1.0 Software can potentially improve physician and patient experience by increasing accuracy of diagnosis and application of therapies. It takes the guesswork out of stent placement."

The new Ultreon 1.0 Software was showcased at the India MedTech Expo held at Gandhinagar from August 17 – 19, 2023.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries. In India, Abbott was established in 1910, and is one of the country's oldest and most admired healthcare companies. With more than 12,000 employees in the country, Abbott is helping to meet the healthcare needs of consumers, patients and doctors throughout urban and rural India.

Connect with us at www.abbott.com and www.abbott.in, on Facebook at www.facebook.com/Abbott and www.facebook.com/AbbottIndia, and on Twitter @AbbottNews. 


Abbott Media:

Nandini Goswami: nandini.goswami@abbott.com
Mandira Viegas: mandira.viegas@abbott.com  


References:

1 https://abbott.mediaroom.com/2020-06-26-New-Research-Finds-Abbotts-Optical-Coherence-Tomography-Imaging-Changed-Treatment-Decisions-in-88-of-Artery-Blockages

2 https://www.cardiovascular.abbott/us/en/campaigns/beyond-intervention.html